NEWS: Curebase closes $40M Series B with strategic investment by Gilead. Read about it in TechCrunch, Fierce Biotech, andEndpoints News.
Featured News
3 mins
May 5, 2022
Curebase closes $40M Series B led by Industry Ventures, with strategic investment by Gilead Sciences.
Fierce Biotech
TechCrunch
Endpoints News
Decentralized Clinical Trials Help Level the Playing Field for Health Equity
PUBLISHED
April 8, 2022
The Growing Case for Digital Therapeutics
January 31, 2022
2022 Predictions for Health Equity
January 14, 2022
Note to File Podcast - Episode 45: Jane Myles, Decentralized Clinical Trials: Evidence of Impact
April 26, 2022
Note to File Podcast - Episode 41: Jane Myles, VP Innovation at Curebase
March 29, 2022
Creating New Decentralized Clinical Trial Ecosystem Including Bring Your Own Physician Option with Tom Lemberg Curebase
January 18, 2022
5 MINS
September 20, 2022
Curebase and Meru Health announce partnership on three-year clinical trial.
3 MINS
August 30, 2022
August 23, 2022
August 16, 2022
Interested in staying up to date with Curebase's latest developments in the decentralized clinical trial space? Get regular updates on news, webinars, blogs and more by subscribing here.
.svg)
%201.svg){kind=logo}
.jpg)
.jpg)
.jpg)
